ORPHA:99867
Thymoma
Publications
402,676
Trials
76
Interventional, condition-specific
Researchers
1,241
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Thymoma is a thymic epithelial neoplasm (TEN), a rare malignancy that arises from the epithelium of the thymic gland.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006456
- MeSH:D013945
- UMLS:C0040100
- NCIT:C3411
Additional Mondo synonyms (5)
primary thymic epithelial neoplasm · primary thymic epithelial tumor · primary thymic epithelial tumour · thymoma · thymoma (disease)
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
402,676 matched papers (274,248 in last 10 years) Source
- Phenotype characterisedPresent
40 HPO annotations (e.g. Neoplasm; Thymoma; Respiratory insufficiency) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
76 matched on ClinicalTrials.gov (17 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
40
Associated phenotypes · MONDO:0006456
- Neoplasm
- Thymoma
- Respiratory insufficiency
- Cough
- Night sweats
Showing 5 of 40 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
45
Drugs / clinical candidates · MONDO_0006456
- CISPLATIN·phase 3
- ETOPOSIDE·phase 3
- AMRUBICIN·phase 2
- AVELUMAB·phase 2
- BELINOSTAT·phase 2
- BEVACIZUMAB·phase 2
- BINTRAFUSP ALFA·phase 2
- BUPARLISIB·phase 2
- CARBOPLATIN·phase 2
- CATEQUENTINIB·phase 2
- CETUXIMAB·phase 2
- CIXUTUMUMAB·phase 2
- CYCLOPHOSPHAMIDE·phase 2
- DOCETAXEL·phase 2
- DOMVANALIMAB·phase 2
CTD chemicals (MyDisease.info)
2 associated chemicals · 165 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Octreotide · therapeutic
- Penicillamine · marker/mechanism
Pathways: Endocrine resistance; Platinum drug resistance; MAPK signaling pathway; Sphingolipid signaling pathway; Cell cycle; p53 signaling pathway; Mitophagy - animal; PI3K-Akt signaling pathway
Literature
Is anyone studying this?
402,676
402,676 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
402,676 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
274,248 in the last 10 years · low confidence
Phrase hits: 402,676 · MeSH hits: 13,391
Who's working on it?
1,241
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li Y6 papers · 2026
Department of Cardio-thoracic Surgery, 900 Hospital of Joint Logistic Support Force PLA, School of Clinical Medicine affiliated to Fujian Medical University, Fuzhou, 350001, China.
Papers in Europe PMC - 02Liu Y5 papers · 2026
Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Papers in Europe PMC - 03Zhang X5 papers · 2026
State Key Laboratory of Pathogenesis, Prevention, and Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Papers in Europe PMC - 04Chen J4 papers · 2026
Huashan Rare Disease Center & Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Papers in Europe PMC - 05Liu J4 papers · 2026
Department of Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China.
Papers in Europe PMC - 06Wang F4 papers · 2026
Department of Obstetrics and Gynecology, The Second Hospital of Hebei Medical University, No. 215 Heping Xi Road, Shijiazhuang, 050000, Hebei, China.
Papers in Europe PMC - 07Wang J4 papers · 2026
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an.
Papers in Europe PMC - 08Xu H4 papers · 2026
Department of Clinical Laboratory, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.
Papers in Europe PMC - 09Zhang L4 papers · 2026
Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Papers in Europe PMC - 10Zhang Y4 papers · 2026
Department of Stomatology, The People's Hospital of Pingyang, Pingyang County, Wenzhou City, Zhejiang Province, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
76
interventional trials for this specific condition
76 interventional trials matched this specific condition name; 17 currently recruiting in our sample.
Data as of 11 September 2026
76 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 98.1th percentile).
low confidence · 98.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
76 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05104736·RECRUITING·PT-112 in Subjects With Thymoma and Thymic Carcinoma
Not reviewed·Conditions: Thymic Epithelial Tumor · Recurrent Thymoma · Thymic Cancer·Matched via name + MeSH
- NCT02633553·RECRUITING·Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
Not reviewed·Conditions: Thymoma·Matched via name + MeSH
- NCT04731610·RECRUITING·Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)
Not reviewed·Conditions: Thymoma Malignant Recurrent·Matched via name + MeSH
- NCT07231523·NOT YET RECRUITING·EFG vs IVIG in TAMG
Not reviewed·Conditions: Efgartigimod · Intravenous Immunoglobulin · Myasthenia Gravis Associated With Thymoma·Matched via name + MeSH
- NCT06248515·RECRUITING·A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Not reviewed·Conditions: Thymoma · Thymic Carcinoma·Matched via name + MeSH
- NCT06838910·RECRUITING·Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
Not reviewed·Conditions: Thymic Carcinoma · Thymoma·Matched via name + MeSH
- NCT07132918·RECRUITING·HEARTS Trial for Thoracic Cancers
Not reviewed·Conditions: Non-Small Cell Lung Cancer (Stage III) · Esophageal Cancer Stage I-III · Esophagogastric Cancer Stage I-III · Thymoma and Thymic Carcinoma Stage II-III·Matched via name + MeSH
- NCT07693855·NOT YET RECRUITING·Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors
Not reviewed·Conditions: Thymus Neoplasms · Thymic Epithelial Tumor · Thymoma · Thymic Carcinoma·Matched via name + MeSH
- NCT07463313·NOT YET RECRUITING·6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
Not reviewed·Conditions: Thymoma and Thymic Carcinoma·Matched via name + MeSH
- NCT06186726·RECRUITING·Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
Not reviewed·Conditions: Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy·Matched via name + MeSH
- NCT03295227·RECRUITING·Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
Not reviewed·Conditions: Stage III Thymoma AJCC v8 · Stage IIIA Thymoma AJCC v8 · Stage IIIB Thymoma AJCC v8 · Stage IV Thymoma AJCC v8·Matched via name + MeSH
- NCT06029621·RECRUITING·Robot-assisted vs VATS for Thymoma
Not reviewed·Conditions: Thymoma·Matched via name + MeSH
- NCT06924619·RECRUITING·Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma
Not reviewed·Conditions: Locally Advanced Thymoma·Matched via name + MeSH
- NCT06730308·RECRUITING·Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Not reviewed·Conditions: Thymoma·Matched via name + MeSH
- NCT06221501·NOT YET RECRUITING·Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
Not reviewed·Conditions: Myasthenia Gravis·Matched via MeSH
Observational and natural-history studies
17 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05214612·RECRUITING·Predictors and Prognostic Factors of Myasthenia Gravis Outcome
Not reviewed·Conditions: Myasthenia Gravis · Autoimmune Diseases of the Nervous System · Neuromuscular Junction Diseases · Thymoma·Matched via name + MeSH
- NCT01950572·RECRUITING·Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Not reviewed·Conditions: Thymoma · Stomach Neoplasms · Pancreatic Neoplasms · Mesothelioma·Matched via name + MeSH
- NCT06301945·RECRUITING·Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
Not reviewed·Conditions: Thymic Epithelial Tumor · Thymic Carcinoma · Thymoma · Thymoma and Thymic Carcinoma·Matched via name + MeSH
- NCT06617741·RECRUITING·Myasthenia Gravis Foundation of America Global MG Patient Registry
Not reviewed·Conditions: Myasthaenia Gravis · Myasthenia · Myasthenia Gravis Associated with Thymoma · Myasthenia Gravis Crisis·Matched via name + MeSH
- NCT07328074·NOT YET RECRUITING·Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
Not reviewed·Conditions: Thymic Epithelial Tumor · Thymoma · Thymic Carcinoma · Pleural Metastasis·Matched via name + MeSH
- NCT07571525·NOT YET RECRUITING·Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
Not reviewed·Conditions: Myasthenia Gravis (MG) · Myasthenia Gravis Associated With Thymoma · Thymoma·Matched via name + MeSH
- NCT04182984·RECRUITING·TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
Not reviewed·Conditions: Ocular Myasthenia Gravis·Matched via MeSH
- NCT01385722·ENROLLING BY INVITATION·Molecular Analysis of Thoracic Malignancies
Not reviewed·Conditions: Thymus Cancer · Thymoma · Thymic Carcinoma · Lung Cancer·Matched via name + MeSH
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 3 · after dedupe 3 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 3 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (3)
- ctis·2023-508658-24-00·Authorised·EORTC-1525-LCG: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)
skipped — LLM skipped (--skip-llm)
- ctis·2023-508001-25-00·Cancelled·“A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And
Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma
PaTIents. PECATI”.
skipped — LLM skipped (--skip-llm)
- ctis·2022-502345-10-00·Cancelled·The effect of oral folinic acid rescue therapy on pemetrexed induced neutropenia and other toxicity: A randomized open-label trial.
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Thymoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Thymoma" OR "primary thymic epithelial neoplasm" OR "primary thymic epithelial tumor" OR "primary thymic epithelial tumour" OR "thymoma (disease)"
MeSH descriptor terms unioned into the query: Thymoma
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Thymoma" OR "primary thymic epithelial neoplasm" OR "primary thymic epithelial tumor" OR "primary thymic epithelial tumour" OR "thymoma (disease)"
Interventional trials matched via: both, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 76 interventional · 17 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (402676) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T06:26:14.012Z
